Page last updated: 2024-10-20

urea and Angina Pectoris

urea has been researched along with Angina Pectoris in 8 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.

Research Excerpts

ExcerptRelevanceReference
"Administration of landiolol using the presently recommended dosage and administration route causes a decrease in HR without aggravation of hemodynamics in patients with normal cardiac function, but in patients with preoperative EF lower than 50%, it may lead to further deterioration of cardiac function due to a decrease in HR."6.73The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. ( Goto, K; Miyakawa, H; Miyamoto, S; Noguchi, T; Shingu, C, 2007)
"Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time."2.80Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. ( Chen, MM; Chou, W; Eisenberg, P; Escandón, R; Greenberg, BH; Lee, JH; Malik, FI; Megreladze, I; Saikali, KG; Shaburishvili, T; Treshkur, T; Wasserman, SM; Wolff, AA, 2015)
"Administration of landiolol using the presently recommended dosage and administration route causes a decrease in HR without aggravation of hemodynamics in patients with normal cardiac function, but in patients with preoperative EF lower than 50%, it may lead to further deterioration of cardiac function due to a decrease in HR."2.73The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. ( Goto, K; Miyakawa, H; Miyamoto, S; Noguchi, T; Shingu, C, 2007)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19904 (50.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Greenberg, BH1
Chou, W1
Saikali, KG1
Escandón, R1
Lee, JH1
Chen, MM1
Treshkur, T1
Megreladze, I1
Wasserman, SM1
Eisenberg, P1
Malik, FI1
Wolff, AA1
Shaburishvili, T1
Goto, K2
Hagiwara, S1
Hidaka, S1
Yamamoto, S1
Kusaka, J1
Yasuda, N1
Shingu, C2
Noguchi, T2
GILLAM, PM1
PRICHARD, BN1
D'iachenko, TC1
Verovckiĭ, VE1
Ostrovskiĭ, OV1
Iakovlev, AT1
Lopatin, IuM1
Miyamoto, S1
Miyakawa, H1
Leishman, AW1
Sandler, G1
Beevers, DG1
Fairman, MJ1
Hamilton, M1
Harpur, JE1
Auvinen, S1
Konttinen, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina[NCT00682565]Phase 294 participants (Actual)Interventional2008-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Increase in Exercise Duration During ETT-3 vs. ETT-B

(NCT00682565)
Timeframe: 1 day

Interventionseconds (Mean)
Mid Dose Active Drug41.5
High Dose Active Drug40.5
All Placebo60.1

Participants Stopping ETT-3 for Angina at Any Stage

"This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B.~Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina." (NCT00682565)
Timeframe: 1 day

InterventionParticipants (Number)
Mid Dose Active Drug0
High Dose Active Drug7
All Placebo2

Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B

The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day

InterventionParticipants (Number)
Mid Dose Active Drug4
High Dose Active Drug2
All Placebo1

Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)

The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day

InterventionParticipants (Number)
Mid Dose Active Drug0
High Dose Active Drug0
All Placebo1

Participants With 1 mm ST Segment Depression During ETT-3

ST Segment Depression measured by Electrocardiography while performing ETT-3. (NCT00682565)
Timeframe: 1 day

InterventionParticipants (Number)
Mid Dose Active Drug0
High Dose Active Drug1
All Placebo2

Trials

3 trials available for urea and Angina Pectoris

ArticleYear
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
    JACC. Heart failure, 2015, Volume: 3, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, D

2015
The effect of landiolol on cerebral blood flow in patients undergoing off-pump coronary artery bypass surgery.
    Journal of anesthesia, 2010, Volume: 24, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Cerebrovascular Circulation; Coronary Artery Byp

2010
The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease.
    Journal of clinical anesthesia, 2007, Volume: 19, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Cardiac Output; Catheterization,

2007

Other Studies

5 other studies available for urea and Angina Pectoris

ArticleYear
USE OF PROPRANOLOL IN ANGINA PECTORIS.
    British medical journal, 1965, Aug-07, Volume: 2, Issue:5457

    Topics: Angina Pectoris; Aspartate Aminotransferases; Biomedical Research; Blood; Clinical Enzyme Tests; Dru

1965
[Informative value of plasma biochemical parameters in acute and chronic coronary heart disease].
    Klinicheskaia laboratornaia diagnostika, 2007, Issue:6

    Topics: Acute Disease; Aged; Angina Pectoris; Bilirubin; Blood Chemical Analysis; Blood Glucose; Blood Prote

2007
Guanethidine and hypertension after five years.
    Angiology, 1967, Volume: 18, Issue:11

    Topics: Albuminuria; Angina Pectoris; Blood Pressure; Cerebrovascular Disorders; Female; Follow-Up Studies;

1967
Antihypertensive treatment and the course of established cerebral vascular disease.
    Lancet (London, England), 1973, Jun-23, Volume: 1, Issue:7817

    Topics: Angina Pectoris; Antihypertensive Agents; Cardiomegaly; Cerebrovascular Disorders; Diuretics; Female

1973
The diagnostic value of serum LDH isoenzymes and heat-stable and urea-stable LDH measurements.
    Acta medica Scandinavica, 1971, Volume: 189, Issue:3

    Topics: Alanine Transaminase; Alkaline Phosphatase; Angina Pectoris; Clinical Enzyme Tests; Electrophoresis;

1971